Switching to iGlarLixi vs Continuation of Glucagon-Like Peptide-1 Receptor Agonist in Inadequately Controlled Type 2 Diabetes Mellitus: The Randomised LixiLan-G Trial - Poster

Lawrence Blonde¹, Julio Rosenstock², Stefano Del Prato³, Robert Henry⁴, Naim Shehadeh⁵, Juan Frias⁶, Elisabeth Niemoeller⁷, Elisabeth Souhami⁸, Junlong Wu⁹, Chen Ji⁹, Vanita R. Aroda¹⁰

1 Ochsner Medical Center, New Orleans, LA, USA
2 Dallas Diabetes Research Center at Medical City, Dallas, TX, USA
3 University of Pisa School of Medicine, Pisa, Italy
4 UC San Diego and Veterans Affairs San Diego Healthcare System, Center for Metabolic Research, San Diego, CA, USA
5 Rambam Health Care Campus, Haifa, Israel
6 National Research Institute, Los Angeles, CA, USA
7 Sanofi, Frankfurt, Germany
8 Sanofi, Paris, France
9 Sanofi, Beijing, China
10 MedStar Health Research Institute, Hyattsville, MD, USA, and Brigham and Women’s Hospital, Boston, MA, USA